Breaking News, Collaborations & Alliances

AbbVie & IGI Enter Global Licensing Agreement for Trispecific Antibody

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM).

By: Rachel Klemovitch

Assistant Editor

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001. ISB 2001 was developed using IGI’s proprietary BEAT protein platform for oncology and autoimmune diseases and is a first-in-class CD38xBCMAxCD3 trispecific antibody. It is a T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells, currently in Ph...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters